Table 4

Results of NGS analyses of cytological and histological specimens from primary tumour and metastases from 16 patients with PM from pancreatic cancer

Primary tumourHistological biopsy prior to PIPAC*PF before PIPACHistological peritoneal biopsy after PIPACPF after PIPAC
Patient 1 KRAS (p.Gly12Asp) KRAS (p.Gly12Asp) KRAS (p.Gly12Asp)ND (PIPAC 3 and 4)NA
Patient 2 KRAS (p.Gly12Val)
TP53 (p.Cys275Tyr)
KRAS (p.Gly12Val)NA KRAS (p.Gly12Val) (PIPAC 2 and 3)NA
Patient 3NDNDNAND
(PIPAC 2, 3, 4 and 5)
ND
(PIPAC 5)
Patient 4ND KRAS (p.Gly12Val)ND KRAS (p.Gly12Val) (PIPAC2) KRAS (p.Gly12Val) (PIPAC 2)
Patient 5 KRAS (p.Gly12Asp)
SMAD4 (p.Arg135Ter)
NANA KRAS (p.Gly12Asp) (PIPAC 2)
SMAD4 (p.Arg135Ter) (PIPAC 2)
ND (PIPAC 3)
KRAS (p.Gly12Asp) (PIPAC 4)
KRAS (p.Gly12Asp) (PIPAC 5)
Patient 6 KRAS (Gly12Asp)NANANANA
Patient 7 KRAS (p.Gly12Val) KRAS (p.Gly12Val) (lymph node) NANANA
Patient 8NAND KRAS (p.Gly12Asp)NANA
Patient 9 MET (p.Arg988Cys) MET (p.Arg988Cys) (found in PM biopsy and lymph node biopsy)NANANA
Patient 10ND KRAS (p.Gln61Arg)
SMAD4 (p.Arg361Cys)
KRAS (p.Gln61Arg) KRAS (p.Gln61Arg) (PIPAC 2) KRAS (p.Gln61Arg) (PIPAC 2)
Patient 11 FGFR2 (p.Asn549Lys) KRAS (p.Gly12Asp) NANANA
Patient 12 KRAS
(p.Gly12Asp)
NANANAND (PIPAC 3 and 4)
Patient 13 KRAS (p.Gly12Val)NANANANA
Patient 14 KRAS (p.Gly12Val)
TP53 (p.Arg273His)
NANANANA
Patient 15NA KRAS (p.Gly12Arg) KRAS (p.Gly12Arg) KRAS (p.Gly12Arg) KRAS (p.Gly12Arg) (PIPAC 2)
Patient 16NA KRAS (p.Gly12Ala)NDNDND (PIPAC 2)
  • *NGS of histological biopsy from peritoneum, unless something else is stated.

  • NA, not available; ND, not detected; NGS, next-generation sequencing; PF, peritoneal fluid; PM, peritoneal metastasis.